Back to search
FDAFDA · Food and drugs·Recall number Z-2580-2024

VITROS Immunodiagnostic VITROS Folate Reagent Pack 1/2

Published August 21, 2024 · Recall initiated: July 3, 2024

Summary

FDA records medical device Class II recall Z-2580-2024, published August 21, 2024 and initiated July 3, 2024. Recalling firm: Ortho-Clinical Diagnostics, Inc.; Status: Ongoing; Reported quantity: 18,467 units; Lot: Model No 1513266; UDI/GTIN# 110758750009237; Lots within expiry: 3380, 3390, 3400, 3410, 3422, 3430, 3440, 3450, 3461, 3471, 3480. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

It was confirmed that fibrinogen in patient plasma samples precipitates out of solution upon the addition of folate stabilizer reagent as part of the pre-treatment process causing the increase in "TM5-4MB" condition codes which lead to a delay of results.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ortho-Clinical Diagnostics, Inc.
Distributor
Worldwide distribution - US Nationwide and the countries of Australia, Belgium, Bermuda, Brazil, Canada, Chile, China, Columbia, Denmark, France, Germany, India, Italy, Japan, Mexico, Netherlands, Norway, Portugal, Russia, Singapore, Sweden, United Kingdom.
Lot
Model No 1513266; UDI/GTIN# 110758750009237; Lots within expiry: 3380, 3390, 3400, 3410, 3422, 3430, 3440, 3450, 3461, 3471, 3480.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was VITROS Immunodiagnostic VITROS Folate Reagent Pack 1/2 recalled?

Yes. FDA published recall Z-2580-2024 on August 21, 2024. Reported hazard: It was confirmed that fibrinogen in patient plasma samples precipitates out of solution upon the addition of folate stabilizer reagent as part of the pre-treatment process causing the increase in "TM5-4MB" condition codes which lead to a delay of results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter